Avey Leaves 23andMe to Start Alzheimer's Research Foundation Using DTC Genomics Firm's Platform | GenomeWeb

By Turna Ray

23andMe co-founder Linda Avey announced last week that she will leave the helm of the Mountain View, Calif.-based personal genomics firm she helped launch in order to start a new research foundation focused on Alzheimer's disease.

The foundation will use 23andMe's research platform and its database of genetic risk association information to investigate the causes and discover new treatments for the disease.

Avey's departure was effective as of Sept. 4, the day the announcement was made.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.